Invokana Diabetic Ketoacidosis
A study published in the New England Journal of Medicine in June 2017 found that Invokana doubles the risk of ketoacidosis compared to diabetes drugs in the DPP-4 inhibitor class. According to the study, it is estimated 5 to 8 patients per 1,000 starting Invokana will develop ketoacidosis, a life-threatening condition involving too much acid in the blood.
The study reviewed data from 50,220 people with type-2 diabetes who started taking an SGLT2 inhibitor and 90,132 people with type-2 diabetes who started taking a DPP-4 inhibitor. It is the largest study to compare the risk of ketoacidosis from these drugs.
Invokana medications prevent hyperglycemia (high blood-sugar levels) by allowing the kidneys remove excess blood sugar via the urine.
DPP-4 (dipeptidyl peptidase-4) inhibitors work by blocking a hormone that causes the body to release glucose into the bloodstream. DPP-4 inhibitor medications include Januvia, Janumet, Onglyxa, Kombiglyze, Tradjenta, Glyaxmbi, Jentadueto, Nesina, Kazano, and Oseni.
What is Diabetic Ketoacidosis?
Diabetic ketoacidosis (DKA) is a serious complication of diabetes that occurs when the body produces high levels of blood ketones.
DKA develops when the body is unable to produce enough insulin. Insulin plays a key role in helping sugar (glucose) — a major source of energy for the muscles and other tissues — enter the cells.
Without enough insulin, the body begins to break down fat as an alternate fuel source. This process produces a buildup of toxic acids in the bloodstream called ketones, eventually leading to diabetic ketoacidosis if untreated.
WHAT ARE DIABETIC KETOACIDOSIS SYMPTOMS?
- Decreased alertness
- Deep, rapid breathing
- Dry skin and mouth
- Flushed face
- Frequent urination or thirst that lasts a day or more
- Fruity-smelling breath
- Muscle stiffness or aches
- Nausea and vomiting
- Stomach pain
FDA Safety Warnings for Invokana and Diabetic Ketoacidosis
In May 2015, the FDA issued a Safety Communication after receiving 20 reports of diabetic ketoacidosis in patients with type-2 diabetes on SGLT2 inhibitors.
In June 2015, the European Medicines Agency (EMA) released a warning after 101 reports of diabetic ketoacidosis were linked to SGLT2 inhibitors.
In December 2015, the FDA ordered Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, finding that the drug increases the risk of this dangerous medical condition.
DEVELOPED INVOKANA DIABETIC KETOACIDOSIS?
The Dr. Shezad Malik Law Firm is currently accepting Invokana injury cases nationwide, including California, Florida, Illinois, New York and Texas.
If you or somebody you know was diagnosed with diabetic ketoacidosis, kidney failure or lower limb amputations after using Invokana, you should contact our attorneys immediately for a free case consultation. Please use the form to contact our Defective Drug Litigation Team or call us toll-free 24 hours a day at (888) 210-9693 ext. 2.
Our law firm’s principal office is in Dallas and we have offices in Fort Worth, Texas. Dr. Shezad Malik Law Firm represents clients in dangerous drug and dangerous medical device lawsuits nationwide.